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Kounis syndrome: A primary cause  
for the anaphylactic shock
In the important paper of Kuda et al. [1] pub-
lished in ”Cardiology Journal” it was found that 
vasospasm-induced coronary flow reduction is 
a major contributory factor in anaphylactic ven-
tricular dysfunction. The authors concluded that 
during anaphylaxis the ensuing left ventricular dys-
function is attributed mainly to coronary vasocon-
striction-induced myocardial ischemia. These and 
other experimental findings, together with clinical 
observations according to which the anaphylactic 
cardiac shock responds to acute myocardial in-
farction protocol treatment while fluid replacement 
has minimal effect might have profound clinical and 
therapeutic implications as far as Kounis syndrome 
is concerned [2, 3]. The current consensus is that 
during anaphylactic shock, the observed myocardial 
damage and ventricular dysfunction is the result of 
leakage of plasma and volume loss due to systemic 
vasodilatation and increased vascular permeability, 
reduced venous return and depression of cardiac 
output due to coronary hypoperfusion. In Kounis 
anaphylaxis associated coronary syndrome, the 
myocardial dysfunction is the result of acute co-
ronary insufficiency from coronary vasospasm or 
coronary thrombotic obstruction. This syndrome is 
caused by inflammatory mediators released during 
the mast cell degranulation process and platelet 
activation via FcgRI, FcgRII, FceRII, and FceRII 
receptors [4].
Previous animal experiments have shown that 
anaphylaxis induces acute myocardial ischemia, 
decrease in cardiac output by 90%, increase in 
left ventricular end diastolic pressure indicating 
pump failure and initial increase in arterial blood 
pressure. The increase in left ventricular end dia-
stolic pressure suggests that volume loss due to 
an increase in vascular permeability and decreased 
venous return are unlikely to be primary causes 
of the documented depression in cardiac output. 
The authors of this experiment definitely excluded 
peripheral vasodilatation as a cause of the registe-
red anaphylactic cardiac damage [5]. Similarly, in 
a recent study [6], it was found that anaphylactic 
shock decreases cerebral blood flow more than 
what would be expected from severe arterial 
hypotension. This was attributed to direct action 
of anaphylactic mediators on the cerebral arterial 
system and not solely due to arterial hypotension.
In the clinical setting [7], a patient who was 
stung by multiple wasps and developed type I va-
riant of Kounis syndrome with anaphylactic shock 
and myocardial ischemia was treated with 2 L of 
normal saline, adrenaline, hydrocortisone, and 
antihistamines, which did not have any immediate 
effect and the patient recovered in a later stage with 
vasopressors and myocardial infarction protocol 
treatment. In another patient with Kounis syndro-
me due to per-operative anaphylactic shock from 
gelofusine infusion [8] the recovery was achieved 
with intravenous antihistamines, steroids and 
inotropic support while treatment with metara-
minol and epinephrine worsened hypotension and 
annihilated cardiac output.
Differentiating tissue hypoperfusion from pri-
mary tissue suppression due to mast cell mediator 
action on systemic arterial vasculature seems to 
be challenging. In anaphylactic shock, myocardial 
involvement due to vasospasm-induced coronary 
blood flow reduction manifesting as Kounis syn-
drome should be always considered. Clinically, 
combined treatment targeting the primary cause 
of anaphylaxis together with protection of cardiac 
tissue seems to be of paramount importance. More 
studies and more experience are needed to deter-
mine the importance of mediators of anaphylaxis 
in myocardial pathobiology.
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